Embryonal Carcinoma of the Testis
On this page
Direct answer
Embryonal carcinoma is the most primitive and aggressive epithelial germ cell tumour, and although a pure embryonal carcinoma is uncommon, it is the single most frequent component of adult mixed nonseminomatous germ cell tumours. Its pleomorphic cells can differentiate along yolk sac, choriocarcinoma or teratoma lines, which is why both AFP and beta-hCG may be elevated. A dominant embryonal component (over about 50 per cent) with lymphovascular invasion marks clinical stage I disease as high risk for occult metastasis and pushes management towards one adjuvant cycle of BEP or intensive surveillance.
What you must remember
- Peak incidence is younger than seminoma, roughly 20-35 years, presenting as a painful or painless testicular mass; pain is more common than with seminoma.
- Pleomorphic, epithelial-looking cells with frequent mitoses and necrosis; glands, papillae and sheets may coexist in one tumour.
- It can secrete AFP and beta-hCG, so marker elevation does not distinguish it from yolk sac or choriocarcinoma components.
- Lymphovascular invasion on histology is the strongest predictor of relapse in clinical stage I NSGCT.
- Greater than 50 per cent embryonal carcinoma is the classic "high-risk" histology used to select adjuvant chemotherapy.
- Marker half-lives govern response monitoring: AFP about 5-7 days, beta-hCG 24-48 hours; failure to fall on schedule means residual disease.
- Spread is lymphatic first to the retroperitoneal (paraaortic, interaortocaval) nodes, then haematogenous to lung and liver.
How to work through a clinical stage I decision
Take a 28-year-old with a left testicular mass, AFP 90 ng/mL, beta-hCG normal, LDH normal. Inguinal orchidectomy shows mixed germ cell tumour with 60 per cent embryonal carcinoma and lymphovascular invasion. CT chest-abdomen shows no nodes; post-operative markers normalise on schedule. This is clinical stage I NSGCT with high-risk pathology.
Three legitimate pathways exist and the reasoning, not the label, is examinable. Surveillance offers 90 per cent plus long-term cure with salvage chemotherapy reserved for the 30-40 per cent who relapse; it demands reliable follow-up with markers, chest imaging and abdominal CT over five years. Adjuvant chemotherapy with one cycle of BEP cuts relapse to under 5 per cent, at the cost of chemotherapy exposure (including fertility and late cardiovascular risk) in men who were already cured. Primary retroperitoneal lymph node dissection, favoured in some North American centres, stages the retroperitoneum directly and treats the site of first relapse but carries sympathetic-nerve-related ejaculatory morbidity unless nerve-sparing. Most European and Indian practice now favours surveillance in motivated men and single-cycle BEP where follow-up is unreliable — an access reality the viva increasingly acknowledges.
If instead the markers fail to normalise, the patient is marker-positive stage I equivalent to metastatic disease, and chemotherapy is no longer optional.
Where students slip
The classic error is treating "embryonal carcinoma" as a marker-defined entity. A question stem that gives a raised AFP tempts candidates to answer yolk sac tumour even when histology says embryonal carcinoma; the correct reasoning is that embryonal carcinoma harbours mixed differentiation and can produce either marker. The second slip is quoting "T2 disease with vascular invasion" as a staging detail without linking it to management — in NSGCT, lymphovascular invasion is the fact that changes the conversation from reassurance to risk stratification. Finally, do not confuse embryonal carcinoma with spermatocytic tumour (formerly spermatocytic seminoma), an indolent tumour of older men that needs no marker work-up in the same way.
Frequently asked questions
Which histological feature best predicts relapse in clinical stage I NSGCT?
Lymphovascular invasion, closely followed by a predominant embryonal carcinoma component (over 50 per cent). Together they define the high-risk group offered adjuvant BEP or intensive surveillance.
Can embryonal carcinoma cause an elevated beta-hCG?
Yes. Syncytiotrophoblastic elements within the tumour secrete beta-hCG, so embryonal carcinoma can raise AFP, beta-hCG, both, or neither.
What is the significance of more than 50 per cent embryonal carcinoma?
It identifies a high-risk clinical stage I tumour with substantial occult retroperitoneal disease risk, guiding the choice between single-cycle BEP and close surveillance.
How fast should tumour markers fall after orchidectomy?
AFP with a half-life of roughly 5-7 days and beta-hCG of 24-48 hours. Persistent elevation implies metastatic disease despite negative imaging.
What is the first site of spread of postpubertal embryonal carcinoma?
The retroperitoneal lymph nodes along the para-aortic and interaortocaval chains, matching the testicular lymphatic drainage to L1-L4 territory.